University of Washington spinout Icosavax has filed for an initial public offering on the Nasdaq Global Select Market, with financial terms yet to be set.

Icosavax, a US-based vaccine developer based on research at University of Washington (UW), filed for an initial public offering on Tuesday with a $100m placeholder target. The company hopes to list on the Nasdaq Global Select Market under the symbol ICVX. It has not yet set any terms for the proposed offering. Founded in 2017,…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.